Lupus & antiphospholipid syndrome
Multimorbidity in systemic lupus erythematosus in a population-based cohort: the Lupus Midwest Network
Main finding · Multimorbidity, prevalent cohortResult — go to the resultOdds ratio 2.98 95% CI 2.18–4.11Authors' conclusion
Patients with SLE had a higher burden of multimorbidity, even before the onset of the disease. The risk disparity continued after SLE classification and was also seen in a prevalent SLE cohort. Multimorbidity was driven both by SDI-related and unrelated conditions.
Study context
- Population
- Prevalent and incident population-based cohorts of patients with SLE and matched comparators (Lupus Midwest Network); 57 chronic conditions assessed449 prevalent
- Exposure
- SLE vs matched non-SLE comparators
- Outcome
- Multimorbidity (≥2 chronic conditions): prevalence and incidence
Methodological detailsmatched comparators, prevalent and incident cohorts, logistic regression, Cox models
- Matched comparators
- Prevalent and incident cohorts
- Logistic regression
- Cox models
Main finding
Multimorbidity, prevalent cohort · 1 January 2015
Odds ratio
2.98
95% CI 2.18–4.11
SLEvs Comparators
OR 2.98 (95% CI 2.18–4.11)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | |
|---|---|---|
| Multimorbidity at SLE incidence, incident cohort | OR 2.27 (95% CI 1.59–3.27) | |
| Development of multimorbidity after SLE incidence | HR 2.11 (95% CI 1.59–2.80) | |
| Development of multimorbidity, SDI-related conditions · after incidence | HR 2.91 (95% CI 2.17–3.88) | |
| Development of multimorbidity, SDI-unrelated conditions · after incidence | HR 1.73 (95% CI 1.32–2.26) | |
| 0.20.5125Ratio (log scale) |
Original publication
Multimorbidity in systemic lupus erythematosus in a population-based cohort: the Lupus Midwest Network. Rheumatology (Oxford). Published 24 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →